The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Open accessAbstract
Multiple myeloma, which ranks as the second most common hematological malignancy, is known for its great genetic heterogeneity. One pathway, however, stands out in this diverse group. NF-κB pathway is one of the most important pathways in multiple myeloma not only for its role in pathogenesis, but also for its importance in various treatment strategies. Mutations in several major components of the NF-κB pathway and its regulators are present in at least 17% of primary multiple myeloma tumors and 42% of multiple myeloma cell lines. The NF-κB pathway regulates numerous genes, which influence development and pathogenesis of multiple myeloma. This significance of NF-κB for myeloma cells, however, is used against them, as current treatment strategies often use NF-κB as their primary or secondary target.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NF-κB regulates production of angiogenic factors VEGF and Ang-1, contributing to MM angiogenesis.
“Additionally, it regulates the production of angiogenic factors such as VEGF and angiopoietin-1 (Ang-1), contributing to MM angiogenesis [61, 143].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [61]
Approximately 80% of MM patients exhibit elevated levels of NF-κB p65 subunits in bone marrow samples.
“Approximately 80% of MM patients exhibit elevated levels of NF-κB p65 subunits in bone marrow samples [60, 61, 138, 139].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [61]
Aberrant activation of NF-κB signaling is crucial in MM pathogenesis.
“The aberrant activation of NF-κB signaling is crucial in MM pathogenesis.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [61]
Cites
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766 · see citing works
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · see citing works
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · see citing works
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024 · see citing works
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma
Akhtar, S., Ali, T. A., Faiyaz, A., Khan, O. S., Raza, S. S., Kulinski, M., Omri, H. E., Bhat, A. A., & Uddin, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145002 · Cited by 44 · see citing works
Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells
Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Lucantonio, L., Gismondi, A., Santoni, A., & Fionda, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031823 · Cited by 26 · see citing works
Nrf2 signaling pathway: focus on oxidative stress in osteoporosis
Gu, H.-Y., Liu, N., Lin, F.-X., & Yin, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07592-0 · Cited by 10 · see citing works
- Authors
- Vrábel, D., Pour, L., & Ševčíková, S.
- Affiliations
- Masaryk University (CZ)
- University Hospital Brno (CZ)
- Corresponding author
- Pour, Luděk
- Venue
- Blood Reviews
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 34
- Pages
- 56-66
- ISSN
- 0268-960X (ISSN-L)
- OpenAlex
- W2900464803
- Cited by
- 123
- References
- 5
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 25 · 2023: 25 · 2022: 13 · 2021: 27 · 2020: 14 · 2019: 2
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Blood Reviews (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- ministry of healthcare of Czech Republic (AZV 15-29508A)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- multiple myeloma, NF-κB signaling, myeloma pathogenesis, genetic heterogeneity, hematologic malignancies
- MeSH terms
- Animals, Antineoplastic Agents, Bone Marrow, Enzyme Activation, Humans, Multiple Myeloma, Signal Transduction, NF-kappa B, Disease Management, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
